Oncology Phase 3 Readout Calendar

Industry-sponsored oncology trials with primary completion in the next 12 months or last 12 months.

Data last updated July 17, 2026 · source: ClinicalTrials.gov

Pro feature

All areas OncologyImmunology Metabolic CNS Cardiovascular Infectious Disease Respiratory Rare Disease Ophthalmology Dermatology Musculoskeletal Renal Pain

126

Next 6 months

224

Next 12 months

Results posted

1,022

Phase 3 Oncology

What you can answer with this page

A confidence-graded calendar of every industry Phase 3 oncology trial reading out in the next 12 months — with a per-row staleness flag so you know which completion dates are still credible.

What oncology trials are reading out soon?

The "upcoming" section shows industry-sponsored Phase 3 oncology trials with primary completion ahead, soonest first, each graded by how credible that date is.

Which oncology trials have already read out?

The "recently read out" section shows Phase 3 oncology trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline.

How are these readout dates sourced?

Every date is the ClinicalTrials.gov primary completion date — the only public, structured signal. We grade each by whether it is actual or sponsor-estimated, and by how recently the trial record was updated.

Where can I see readouts for other therapeutic areas?

The full cross-area calendar is on the main readout calendar; this page is the Oncology slice of it.

Recently read-out results are free; the upcoming calendar shows a free preview. See the full cross-area calendar → or the Oncology landscape →

Recently read out & awaiting topline — Oncology

· 47

Phase 3 oncology trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline. Most recent first.

Sponsor	Trial / Asset	Indication	Status	Primary completion	Confidence	NCT
Arog Pharmaceuticals, Inc.	Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Asset: Crenolanib	Newly Diagnosed FLT3 Mutated AML	Completed	Q2 2026 2026-04-06	Completed · awaiting Updated 3mo ago	NCT03258931
Arog Pharmaceuticals, Inc.	Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML Asset: Crenolanib	Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations	Completed	Q2 2026 2026-04-03	Completed · awaiting Updated 3mo ago	NCT03250338
Sandoz	A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Asset: GME751	Metastatic NSCLC	Completed	Q1 2026 2026-03-16	Completed · awaiting Updated 3mo ago	NCT06159790
Regeneron Pharmaceuticals	Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma Asset: Fianlimab	Melanoma	Active Not Recruiting	Q1 2026 2026-03-12	Completed · awaiting Updated 3mo ago	NCT05352672
Merck Sharp & Dohme LLC	A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) Asset: Pembrolizumab (+) Berahyaluronidase alfa	Lung Cancer +1	Active Not Recruiting	Q1 2026 2026-03-12	Completed · awaiting Updated 4mo ago	NCT06698042
AstraZeneca	Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC Asset: Tremelimumab	Hepatocellular Carcinoma	Active Not Recruiting	Q1 2026 2026-02-23	Completed · awaiting Updated 3mo ago	NCT05301842
Karyopharm Therapeutics Inc	Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis Asset: Selinexor	Myelofibrosis	Active Not Recruiting	Q1 2026 2026-02-20	Completed · awaiting Updated 3mo ago	NCT04562389
Pfizer	Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC Asset: talazoparib plus enzalutamide	Prostate Cancer	Active Not Recruiting	Q1 2026 2026-02-18	Completed · awaiting Updated 3mo ago	NCT04821622
Bristol-Myers Squibb	A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer Asset: Nivolumab	Urinary Bladder Neoplasms +1	Active Not Recruiting	Q1 2026 2026-02-16	Completed · awaiting Updated 3mo ago	NCT03661320
Boston Scientific Corporation	MANDARIN (S6371)	Inoperable Hepatocellular Carcinoma	Active Not Recruiting	Q1 2026 2026-02-13	Completed · awaiting Updated 3mo ago	NCT05016245
Merck Sharp & Dohme LLC	A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) Asset: Belzutifan	Carcinoma, Renal Cell	Active Not Recruiting	Q1 2026 2026-02-02	Completed · awaiting Updated 4mo ago	NCT04586231
Hoffmann-La Roche	A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) Asset: Giredestrant	Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer	Active Not Recruiting	Q1 2026 2026-01-30	Completed · awaiting Updated 5mo ago	NCT04546009
Dizal Pharmaceuticals	A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) Asset: sunvozertinib	Non-small Cell Lung Cancer	Active Not Recruiting	Q1 2026 2026-01-16	Completed · awaiting Updated 5mo ago	NCT05668988
Merck Sharp & Dohme LLC	Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) Asset: pembrolizumab	Hodgkin Lymphoma	Completed	Q1 2026 2026-01-14	Completed · awaiting Updated 5mo ago	NCT02684292
Seagen, a wholly owned subsidiary …	Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Asset: Brentuximab vedotin	Diffuse Large B-cell Lymphoma	Active Not Recruiting	Q1 2026 2026-01-12	Completed · awaiting Updated 3mo ago	NCT04404283
Pfizer	A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma Asset: Encorafenib	Melanoma	Active Not Recruiting	Q1 2026 2026-01-12	Completed · awaiting Updated 3mo ago	NCT04657991
Eli Lilly and Company	A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) Asset: Selpercatinib	Carcinoma, Non-Small-Cell Lung	Active Not Recruiting	Q1 2026 2026-01-12	Completed · awaiting Updated 4mo ago	NCT04819100
Innovent Biologics (Suzhou) Co. Ltd.	A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC Asset: IBI310	Hepatocellular Carcinoma	Completed	Q4 2025 2025-12-31	Completed · awaiting Updated 4mo ago	NCT04720716
Hoffmann-La Roche	A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer Asset: Atezolizumab	Non-Small Cell Lung Cancer	Active Not Recruiting	Q4 2025 2025-12-30	Completed · awaiting Updated 3mo ago	NCT05047250
Hoffmann-La Roche	A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer Asset: Atezolizumab	Non-Small Cell Lung Cancer	Completed	Q4 2025 2025-12-30	Completed · awaiting Updated 6mo ago	NCT04294810
Boehringer Ingelheim	Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma Asset: Brigimadlin	Liposarcoma, Dedifferentiated	Completed	Q4 2025 2025-12-12	Completed · awaiting Updated 6mo ago	NCT06058793
BeiGene	Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer Asset: Pamiparib capsule	Ovarian Cancer	Active Not Recruiting	Q4 2025 2025-12-01	Completed · awaiting Updated 4mo ago	NCT03519230
AstraZeneca	Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients Asset: Acalabrutinib	Chronic Lymphocytic Leukemia	Completed	Q4 2025 2025-11-04	Completed · awaiting Updated 8mo ago	NCT04008706
Adlai Nortye Biopharma Co., Ltd.	The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC Asset: Buparlisib & Paclitaxel	Head and Neck Cancer	Completed	Q4 2025 2025-11-02	Completed · awaiting Updated 8mo ago	NCT04338399
Merck Sharp & Dohme LLC	Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) Asset: Pembrolizumab	Bladder Cancer	Active Not Recruiting	Q4 2025 2025-10-27	Completed · awaiting Updated 5mo ago	NCT04700124
R-Pharm	A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer Asset: RPH-051	Locally Advanced Breast Cancer +1	Active Not Recruiting	Q4 2025 2025-10-23	Completed · awaiting Updated 5mo ago	NCT07386938
Amgen	Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. Asset: Bemarituzumab	Gastric Cancer +1	Active Not Recruiting	Q4 2025 2025-10-14	Completed · awaiting Updated 7mo ago	NCT05111626
Merck Sharp & Dohme LLC	Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) Asset: Pembrolizumab	Triple Negative Breast Neoplasms	Completed	Q4 2025 2025-10-14	Completed · awaiting Updated 9mo ago	NCT03036488
Genmab	A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China Asset: Epcoritamab	Diffuse Large B-Cell Lymphoma	Active Not Recruiting	Q4 2025 2025-10-13	Completed · awaiting Updated 3mo ago	NCT07226752
Genmab	A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Asset: Epcoritamab	Diffuse Large B-cell Lymphoma	Active Not Recruiting	Q4 2025 2025-10-13	Completed · awaiting Updated 3mo ago	NCT04628494
Janssen Research & Development, LLC	A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Asset: Teclistamab	Relapsed or Refractory Multiple Myeloma	Active Not Recruiting	Q4 2025 2025-10-13	Completed · awaiting Updated 3mo ago	NCT05572515
AstraZeneca	A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy Asset: Ceralasertib	Advanced or Metastatic Non-Small Cell Lung Cancer	Active Not Recruiting	Q4 2025 2025-10-06	Completed · awaiting Updated 3mo ago	NCT05450692
AstraZeneca	Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) Asset: Durvalumab	Biliary Tract Cancer	Active Not Recruiting	Q4 2025 2025-10-02	Completed · awaiting Updated 3mo ago	NCT05771480
Servier	Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation Asset: Vorasidenib	Residual or Recurrent Grade 2 IDH Mutant Glioma	Active Not Recruiting	Q4 2025 2025-10-02	Completed · awaiting Updated 6mo ago	NCT06780930
Bristol-Myers Squibb	A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants Asset: Luspatercept	Myelodysplastic Syndromes	Active Not Recruiting	Q4 2025 2025-10-01	Completed · awaiting Updated 8mo ago	NCT06045689
Cogent Biosciences, Inc.	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors Asset: CGT9486	Advanced Gastrointestinal Stromal Tumors +1	Recruiting	Q3 2025 2025-09-30	Completed · awaiting Updated 5mo ago	NCT05208047
R-Pharm	A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma Asset: RPH-002	Head and Neck Squamous Cell Carcinoma	Completed	Q3 2025 2025-09-29	Completed · awaiting Updated 5mo ago	NCT07435324
Octapharma	Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) Asset: Panzyga	Chronic Lymphocytic Leukemia +1	Completed	Q3 2025 2025-09-19	Completed · awaiting Updated 9mo ago	NCT04502030
UroGen Pharma Ltd.	A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer Asset: UGN-103	Bladder Cancer +2	Active Not Recruiting	Q3 2025 2025-09-11	Completed · awaiting Updated 6mo ago	NCT06331299
Seagen, a wholly owned subsidiary …	A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer Asset: Tucatinib	HER2 Positive Breast Cancer	Active Not Recruiting	Q3 2025 2025-09-05	Completed · awaiting Updated 3mo ago	NCT05132582
AstraZeneca	A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) Asset: Dato-DXd	Breast Cancer	Active Not Recruiting	Q3 2025 2025-08-25	Completed · awaiting Updated 6mo ago	NCT05374512
Merck Sharp & Dohme LLC	Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) Asset: Lenvatinib	Carcinoma, Hepatocellular	Completed	Q3 2025 2025-08-19	Completed · awaiting Updated 3mo ago	NCT04246177
Shanghai Fudan-Zhangjiang Bio-Phar…	Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid（5-ALA） Asset: 5 Aminolevulinic Acid	5-aminolevulinic Acid +1	Completed	Q3 2025 2025-08-19	Completed · awaiting Updated 4mo ago	NCT06417281
Celgene	A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation Asset: idecabtagene vicleucel	Multiple Myeloma	Active Not Recruiting	Q3 2025 2025-08-11	Completed · awaiting Updated 4mo ago	NCT06045806
Hoffmann-La Roche	A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) Asset: Giredestrant	Early Breast Cancer	Active Not Recruiting	Q3 2025 2025-08-08	Completed · awaiting Updated 5mo ago	NCT04961996
Bristol-Myers Squibb	A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma Asset: Nivolumab + Relatlimab	Melanoma	Active Not Recruiting	Q3 2025 2025-08-04	Completed · awaiting Updated 11mo ago	NCT05625399
Bristol-Myers Squibb	A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread Asset: Nivolumab and rHuPH20	Clear Cell Renal Cell Carcinoma	Active Not Recruiting	Q3 2025 2025-07-29	Completed · awaiting Updated 9mo ago	NCT04810078

Upcoming oncology readouts — next 12 months

· 224

Industry Phase 3 oncology trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.

Sponsor	Trial / Asset	Indication	Status	Primary completion	Confidence	NCT
Bristol-Myers Squibb	A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) Asset: Mezigdomide	Relapsed or Refractory Multiple Myeloma	Active Not Recruiting	Q3 2026 2026-07-18 (est.)	Estimated · fresh Updated 4mo ago	NCT05552976
AstraZeneca	D9319C00001- 1L OC Mono Global RCT Asset: Olaparib	Ovarian Cancer	Active Not Recruiting	Q3 2026 2026-07-27 (est.)	Estimated · fresh Updated 5mo ago	NCT04884360
Jiangsu HengRui Medicine Co., Ltd.	A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma Asset: TACE+Camrelizumab+Apatinib mesylate	Hepatocellular Carcinoma	Active Not Recruiting	Q3 2026 2026-07-30 (est.)	Estimated · aging Updated 7mo ago	NCT05320692
CSPC Megalith Biopharmaceutical Co…	Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01） Asset: SYS6010	EGFR-mutated Locally Advanced or Metastatic NSCLC	Recruiting	Q3 2026 2026-07-30 (est.)	Estimated · aging Updated 8mo ago	NCT06927986
Shenyang Sunshine Pharmaceutical C…	SSGJ-707 in Advanced Non-Small Cell Lung Cancer Asset: SSGJ-707	Advanced Non-Small Cell Lung Cancer	Recruiting	Q3 2026 2026-07-30 (est.)	Estimated · stale Updated 13mo ago	NCT06980272
Sichuan Kelun-Biotech Biopharmaceu…	A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer Asset: SKB264	Triple Negative Breast Cancer	Recruiting	Q3 2026 2026-07 (est.)	Estimated · fresh Updated 6mo ago	NCT06279364
Merck Sharp & Dohme LLC	Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) Asset: Pembrolizumab	High-risk Non-muscle Invasive Bladder Cancer	Active Not Recruiting	Q3 2026 2026-07-31 (est.)	Estimated · aging Updated 7mo ago	NCT03711032
Jazz Pharmaceuticals	A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers Asset: Zanidatamab	Gastric Neoplasms +2	Active Not Recruiting	Q3 2026 2026-07-31 (est.)	Estimated · fresh Updated 3mo ago	NCT05152147
Jiangsu HengRui Medicine Co., Ltd.	A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation Asset: Camrelizumab	Hepatocellular Carcinoma (HCC)	Active Not Recruiting	Q3 2026 2026-07-31 (est.)	Estimated · aging Updated 7mo ago	NCT04639180
Camurus AB	A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET Asset: CAM2029	Gastro-enteropancreatic Neuroendocrine Tumor	Active Not Recruiting	Q3 2026 2026-07 (est.)	Estimated · aging Updated 8mo ago	NCT05050942
HUYABIO International, LLC.	Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma Asset: HBI-8000 in combination with nivolumab	Unresectable or Metastatic Melanoma +1	Active Not Recruiting	Q3 2026 2026-07 (est.)	Estimated · aging Updated 10mo ago	NCT04674683
Shanghai Hengrui Pharmaceutical Co…	A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma Asset: SHR-A2102 for Injection	Advanced Urothelial Carcinoma	Recruiting	Q3 2026 2026-07 (est.)	Estimated · aging Updated 12mo ago	NCT06738251
Sichuan Baili Pharmaceutical Co., …	A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma Asset: SI-B001	Non-small Cell Lung Adenocarcinoma +1	Active Not Recruiting	Q3 2026 2026-07 (est.)	Estimated · stale Updated 13mo ago	NCT05943795
InnoPharmax Inc.	Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer Asset: D07001-softgel capsules + Xeloda (or TS-1)	Biliary Tract Cancer	Recruiting	Q3 2026 2026-07 (est.)	Estimated · stale Updated 15mo ago	NCT05065957
SUNHO（China）BioPharmaceutical CO.,…	To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer Asset: IAH0968	Stomach Neoplasms +1	Recruiting	Q3 2026 2026-07 (est.)	Estimated · stale Updated 18mo ago	NCT06504732
Daiichi Sankyo	A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) Asset: T-DXd	Advanced Cancer +1	Recruiting	Q3 2026 2026-08-03 (est.)	Estimated · aging Updated 9mo ago	NCT06174987
Shanghai Fudan-Zhangjiang Bio-Phar…	FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer Asset: FDA018-ADC	Triple Negative Breast Cancer	Active Not Recruiting	Q3 2026 2026-08-18 (est.)	Estimated · fresh Updated 6mo ago	NCT06519370
Merck Sharp & Dohme LLC	Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) Asset: pembrolizumab/vibostolimab	Carcinoma, Non-Small-Cell Lung	Active Not Recruiting	Q3 2026 2026-08-19 (est.)	Estimated · aging Updated 12mo ago	NCT05298423
EMD Serono Research & Development …	Avelumab Program Rollover Study Asset: Avelumab	Solid Tumors	Active Not Recruiting	Q3 2026 2026-08-21 (est.)	Estimated · fresh Updated 4mo ago	NCT03815643
AstraZeneca	A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease Asset: AZD9833	ER-Positive HER2-Negative Breast Cancer	Active Not Recruiting	Q3 2026 2026-08-24 (est.)	Estimated · aging Updated 9mo ago	NCT04711252
Novartis Pharmaceuticals	Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer Asset: JDQ443	Non-Small Cell Lung Cancer	Active Not Recruiting	Q3 2026 2026-08-25 (est.)	Estimated · fresh Updated 3mo ago	NCT05132075
Panbela Therapeutics, Inc.	Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer Asset: SBP-101	Pancreatic Cancer Metastatic +2	Recruiting	Q3 2026 2026-08-29 (est.)	Estimated · stale Updated 20mo ago	NCT05254171
Pfizer	MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) Asset: Elranatamab	Multiple Myeloma	Recruiting	Q3 2026 2026-08-30 (est.)	Estimated · fresh Updated 3mo ago	NCT06152575
Hutchison Medipharma Limited	Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC Asset: Savolitinib	Non-small Cell Lung Cancer	Active Not Recruiting	Q3 2026 2026-08-30 (est.)	Estimated · aging Updated 11mo ago	NCT05009836
Daiichi Sankyo	Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) Asset: Trastuzumab deruxtecan	Gastric Cancer, Adenocarcinoma +1	Active Not Recruiting	Q3 2026 2026-08-31 (est.)	Estimated · fresh Updated 6mo ago	NCT04704934
Karyopharm Therapeutics Inc	Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma Asset: Selinexor	Endometrial Cancer	Active Not Recruiting	Q3 2026 2026-08 (est.)	Estimated · fresh Updated 3mo ago	NCT05611931
Hansoh BioMedical R&D Company	Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure Asset: HS-20093	Osteosarcoma	Active Not Recruiting	Q3 2026 2026-08-31 (est.)	Estimated · fresh Updated 3mo ago	NCT06935409
AbbVie	A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. Asset: Pomalidomide	Multiple Myeloma	Active Not Recruiting	Q3 2026 2026-08 (est.)	Estimated · stale Updated 13mo ago	NCT03539744
Sunshine Lake Pharma Co., Ltd.	Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer Asset: Lerotinib	Esophageal Cancer	Recruiting	Q3 2026 2026-08 (est.)	Estimated · stale Updated 14mo ago	NCT04415853
Yantai LNC Biotechnology Singapore…	Clinical Study of 18F-Alfatide Injection PET/CT Asset: 18F-Alfatide Injection	Non-Small Cell Lung Cancer NSCLC	Not Yet Recruiting	Q3 2026 2026-08 (est.)	Estimated · stale Updated 26mo ago	NCT06416852
Incyte Corporation	Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients Asset: Tafasitamab	Diffuse Large B-cell Lymphoma	Active Not Recruiting	Q3 2026 2026-09-01 (est.)	Estimated · fresh Updated 4mo ago	NCT04824092
Boehringer Ingelheim	Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment Asset: zongertinib	Lung Cancer, Non-squamous, Non-small Cell	Active Not Recruiting	Q3 2026 2026-09-02 (est.)	Estimated · fresh Updated 3mo ago	NCT06151574
Merck Sharp & Dohme LLC	Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) Asset: Pembrolizumab	Endometrial Neoplasms	Active Not Recruiting	Q3 2026 2026-09-15 (est.)	Estimated · stale Updated 13mo ago	NCT04634877
Han Xu, M.D., Ph.D., FAPCR, Sponso…	Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms Asset: Topotecan - usual	SCLC	Active Not Recruiting	Q3 2026 2026-09-18 (est.)	Estimated · aging Updated 10mo ago	NCT07145333
Clarity Pharmaceuticals Ltd	Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy Asset: 64Cu-SAR-bisPSMA	Prostate Cancer +1	Recruiting	Q3 2026 2026-09 (est.)	Estimated · fresh Updated 3mo ago	NCT06056830
Pfizer	Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Asset: Avelumab	Advanced Malignancies +4	Active Not Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · fresh Updated 3mo ago	NCT05059522
Curium US LLC	Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer Asset: Copper Cu 64 PSMA I&T	Prostate Cancer +1	Recruiting	Q3 2026 2026-09 (est.)	Estimated · fresh Updated 3mo ago	NCT06235151
AstraZeneca	A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Asset: Dato-DXd	Metastatic Non-small Cell Lung Cancer	Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · fresh Updated 5mo ago	NCT06417814
Beijing Pearl Biotechnology Limite…	A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2) Asset: PLB1001	Non-small Cell Lung Cancer	Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · stale Updated 13mo ago	NCT05989542
Innovent Biologics (Suzhou) Co. Ltd.	Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer Asset: Pemetrexed	Non-Small Cell Lung Cancer	Active Not Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · stale Updated 13mo ago	NCT05116462
Mabwell (Shanghai) Bioscience Co.,…	A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer Asset: 9MW2821	Advanced Urothelial Carcinoma	Recruiting	Q3 2026 2026-09 (est.)	Estimated · stale Updated 15mo ago	NCT06196736
Allist Pharmaceuticals, Inc.	JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation Asset: JAB-21822	Advanced Non-squamous Non-small-cell Lung Cancer +1	Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · stale Updated 15mo ago	NCT06416410
Bio-Thera Solutions	BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer Asset: Recombinant humanized anti-PD-1 monoclonal antibody injection	Cervical Cancer	Recruiting	Q3 2026 2026-09 (est.)	Estimated · stale Updated 17mo ago	NCT06123884
Shanghai JMT-Bio Inc.	A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations Asset: JMT101	Locally Advanced or Metastatic Non-squamous NSCLC +2	Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · stale Updated 19mo ago	NCT06735391
Hansoh BioMedical R&D Company	ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer Asset: HS-20093	Small Cell Lung Cancer	Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · stale Updated 21mo ago	NCT06498479
Chia Tai Tianqing Pharmaceutical G…	A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients Asset: TQB2450+Anlotinib	Small Cell Lung Cancer Limited Stage	Not Yet Recruiting	Q3 2026 2026-09 (est.)	Estimated · stale Updated 25mo ago	NCT06469879
Janssen Research & Development, LLC	A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC Asset: Apalutamide	Metastatic Castrate-sensitive Prostate Cancer	Active Not Recruiting	Q4 2026 2026-10-12 (est.)	Estimated · fresh Updated 4mo ago	NCT05884398
Shanghai JMT-Bio Inc.	JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer Asset: JSKN003	Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants	Recruiting	Q4 2026 2026-10-13 (est.)	Estimated · stale Updated 16mo ago	NCT06846437
Merck Sharp & Dohme LLC	A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) Asset: Belzutifan	Carcinoma, Renal Cell	Active Not Recruiting	Q4 2026 2026-10-28 (est.)	Estimated · aging Updated 11mo ago	NCT05239728
Akeso	A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC Asset: Cadonilimab (AK104)	NSCLC (Non-small Cell Lung Cancer)	Recruiting	Q4 2026 2026-10-28 (est.)	Estimated · stale Updated 16mo ago	NCT06617416
Merck Sharp & Dohme LLC	A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) Asset: Pembrolizumab	Carcinoma, Renal Cell	Active Not Recruiting	Q4 2026 2026-10-29 (est.)	Estimated · stale Updated 20mo ago	NCT04736706
Laekna Limited	Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Asset: Afuresertib	Breast Cancer	Active Not Recruiting	Q4 2026 2026-10-30 (est.)	Estimated · fresh Updated 4mo ago	NCT04851613
UroGen Pharma Ltd.	A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer Asset: UGN-104	Upper Urinary Tract Urothelial Carcinoma +1	Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 6mo ago	NCT06774131
Privo Technologies	A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers Asset: PRV211 (Intraoperative Cisplatin System)	Oral Squamous Cell Carcinoma	Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 3mo ago	NCT05893888
Takeda	TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations Asset: TAK-788	Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	Active Not Recruiting	Q4 2026 2026-10-31 (est.)	Estimated · fresh Updated 4mo ago	NCT04129502
AstraZeneca	Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients Asset: Capivasertib	Breast Cancer	Active Not Recruiting	Q4 2026 2026-10-31 (est.)	Estimated · fresh Updated 4mo ago	NCT06635447
Hoffmann-La Roche	A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) Asset: Alectinib	Non-Small Cell Lung Cancer	Active Not Recruiting	Q4 2026 2026-10-31 (est.)	Estimated · fresh Updated 4mo ago	NCT03178552
Loxo Oncology, Inc.	A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Asset: Pirtobrutinib	Chronic Lymphocytic Leukemia +1	Active Not Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 6mo ago	NCT04965493
Akeso	AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer Asset: AK112, Gemcitabine, Cisplatin	Biliary Tract Cancer	Active Not Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 6mo ago	NCT06591520
CSPC ZhongQi Pharmaceutical Techno…	Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors Asset: Sirolimus for Injection (Albumin-bound)	HR+/HER2- Advanced/Metastatic Breast Cancer	Not Yet Recruiting	Q4 2026 2026-10 (est.)	Estimated · stale Updated 15mo ago	NCT06929325
Immutep S.A.S.	Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitaxel Chemotherapy Asset: eftilagimod alpha	Breast Carcinoma	Active Not Recruiting	Q4 2026 2026-10-31 (est.)	Estimated · stale Updated 19mo ago	NCT05747794
Jiangsu HengRui Medicine Co., Ltd.	Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative Asset: SHR6390	Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer	Active Not Recruiting	Q4 2026 2026-10-31 (est.)	Estimated · stale Updated 24mo ago	NCT04842617
Chia Tai Tianqing Pharmaceutical G…	D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure Asset: D-1553 Tablet	Non Small Cell Lung Cancer	Recruiting	Q4 2026 2026-10 (est.)	Estimated · stale Updated 27mo ago	NCT06300177
Han Xu, M.D., Ph.D., FAPCR, Sponso…	Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms Asset: Alectinib - Usual	ALK-Positive Non-Small Cell Lung Cancer (NSCLC)	Active Not Recruiting	Q4 2026 2026-11-18 (est.)	Estimated · fresh Updated 3mo ago	NCT05987956
Han Xu, M.D., Ph.D., FAPCR, Sponso…	Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms Asset: ETOPOSIDE - Usual	Small Cell Lung Cancer	Active Not Recruiting	Q4 2026 2026-11-18 (est.)	Estimated · aging Updated 12mo ago	NCT01064466
Tesaro, Inc.	A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer Asset: Dostarlimab	Neoplasms	Active Not Recruiting	Q4 2026 2026-11-26 (est.)	Estimated · aging Updated 10mo ago	NCT03981796
Sichuan Kelun-Biotech Biopharmaceu…	A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Asset: SKB264	Non-Small Cell Lung Cancer	Active Not Recruiting	Q4 2026 2026-11 (est.)	Estimated · fresh Updated 4mo ago	NCT06448312
InventisBio Co., Ltd	A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer Asset: D-0502	Breast Cancer	Recruiting	Q4 2026 2026-11-30 (est.)	Estimated · fresh Updated 4mo ago	NCT06954961
Qilu Pharmaceutical Co., Ltd.	Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer Asset: QLG1080	Prostate Cancer	Not Yet Recruiting	Q4 2026 2026-11 (est.)	Estimated · stale Updated 17mo ago	NCT06837896
CAS Lamvac (Guangzhou) Biomedical …	Plasmodium Immunotherapy for Advanced Ovarian Cancer Asset: Plasmodium immunotherapy	Advanced Ovarian Cancer	Not Yet Recruiting	Q4 2026 2026-11-30 (est.)	Estimated · stale Updated 24mo ago	NCT05924776
Janssen Research & Development, LLC	A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy Asset: Apalutamide	Prostatic Neoplasms	Active Not Recruiting	Q4 2026 2026-12-01 (est.)	Estimated · fresh Updated 3mo ago	NCT03767244
Shanghai Pharmaceuticals Holding C…	Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer Asset: SPH4336 Tablets	Locally Advanced or Metastatic Breast Cancer	Recruiting	Q4 2026 2026-12-01 (est.)	Estimated · fresh Updated 6mo ago	NCT05860465
Pfizer	A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. Asset: PF-06821497	Metastatic Castration-Resistant Prostate Cancer	Recruiting	Q4 2026 2026-12-02 (est.)	Estimated · fresh Updated 3mo ago	NCT06629779
CSPC Megalith Biopharmaceutical Co…	A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC Asset: SYS6010	NSCLC	Not Yet Recruiting	Q4 2026 2026-12-12 (est.)	Estimated · fresh Updated 5mo ago	NCT07376382
Amgen	Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) Asset: ABP 234	Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)	Active Not Recruiting	Q4 2026 2026-12-14 (est.)	Estimated · fresh Updated 4mo ago	NCT06430866
Shanghai JMT-Bio Inc.	A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer Asset: KN026	Early or Locally Advanced HER2-positive Breast Cancer	Active Not Recruiting	Q4 2026 2026-12-16 (est.)	Estimated · stale Updated 15mo ago	NCT06747338
Han Xu, M.D., Ph.D., FAPCR, Sponso…	Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms Asset: Raloxifene - Usual	Breast Cancer	Active Not Recruiting	Q4 2026 2026-12-18 (est.)	Estimated · fresh Updated 3mo ago	NCT06062810
Hoffmann-La Roche	A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) Asset: Alectinib	Non-Small Cell Lung Cancer	Active Not Recruiting	Q4 2026 2026-12-20 (est.)	Estimated · fresh Updated 4mo ago	NCT05170204
Shanghai Kechow Pharma, Inc.	Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer Asset: Tunlametinib plus Vemurafenib	Colorectal Cancer Metastatic	Recruiting	Q4 2026 2026-12-24 (est.)	Estimated · aging Updated 10mo ago	NCT06008119
Jiangsu Healthy Life Innovation Me…	Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer Asset: Gemcitabine hydrochloride and albumin binding paclitaxel	Locally Advanced Pancreatic Cancer	Recruiting	Q4 2026 2026-12-25 (est.)	Estimated · stale Updated 16mo ago	NCT05653453
CanariaBio Inc.	Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery Asset: Oregovomab	Carcinoma, Ovarian Epithelial +9	Active Not Recruiting	Q4 2026 2026-12-26 (est.)	Estimated · fresh Updated 4mo ago	NCT04498117
Janssen Research & Development, LLC	A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder Asset: Cetrelimab	Urinary Bladder Neoplasms	Active Not Recruiting	Q4 2026 2026-12-30 (est.)	Estimated · fresh Updated 3mo ago	NCT04658862
Pfizer	Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer Asset: Vepdegestrant (ARV-471/PF-07850327)	Breast Cancer	Active Not Recruiting	Q4 2026 2026-12-30 (est.)	Estimated · fresh Updated 5mo ago	NCT05909397
AskGene Pharma, Inc.	ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma Asset: ASKB589	Gastroesophageal Junction Adenocarcinoma +1	Active Not Recruiting	Q4 2026 2026-12-30 (est.)	Estimated · fresh Updated 6mo ago	NCT06206733
Xynomic Pharmaceuticals, Inc.	A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) Asset: Pazopanib	Renal Cell Carcinoma	Recruiting	Q4 2026 2026-12-30 (est.)	Estimated · stale Updated 15mo ago	NCT03592472
Jiangsu vcare pharmaceutical techn…	Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors Asset: VC004 Capsules	Locally Advanced Solid Tumor	Recruiting	Q4 2026 2026-12-30 (est.)	Estimated · stale Updated 16mo ago	NCT06658353
Jiangsu Alphamab Biopharmaceutical…	JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer Asset: JSKN003	Ovarian Cancer +2	Not Yet Recruiting	Q4 2026 2026-12-30 (est.)	Estimated · stale Updated 19mo ago	NCT06751485
Beijing Konruns Pharmaceutical Co.…	A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer Asset: KC1036	Esophageal Squamous Cell Carcinoma	Recruiting	Q4 2026 2026-12-30 (est.)	Estimated · stale Updated 28mo ago	NCT06194734
Hoffmann-La Roche	A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial Asset: Pertuzumab	Solid Tumors	Active Not Recruiting	Q4 2026 2026-12-31 (est.)	Estimated · fresh Updated 5mo ago	NCT02320435
Janssen Research & Development, LLC	A Long-term Extension Study of PCI-32765 (Ibrutinib) Asset: Ibrutinib	Chronic Lymphocytic Leukemia +6	Recruiting	Q4 2026 2026-12-31 (est.)	Estimated · fresh Updated 3mo ago	NCT01804686
Hoffmann-La Roche	A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer Asset: Inavolisib	Metastatic Breast Cancer	Recruiting	Q4 2026 2026-12-31 (est.)	Estimated · fresh Updated 4mo ago	NCT05894239
Swedish Orphan Biovitrum	A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Asset: Pacritinib	Primary Myelofibrosis +2	Active Not Recruiting	Q4 2026 2026-12-31 (est.)	Estimated · fresh Updated 5mo ago	NCT03165734
AstraZeneca	Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab Asset: Durvalumab	Cancer	Enrolling By Invitation	Q4 2026 2026-12-31 (est.)	Estimated · fresh Updated 3mo ago	NCT05303532
Jiangsu HengRui Medicine Co., Ltd.	An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. Asset: Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide	Advanced Gastroenteropancreatic Neuroendocrine Tumor	Recruiting	Q4 2026 2026-12 (est.)	Estimated · fresh Updated 3mo ago	NCT05884255
Chia Tai Tianqing Pharmaceutical G…	Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer Asset: TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen	Breast Cancer	Active Not Recruiting	Q4 2026 2026-12 (est.)	Estimated · fresh Updated 3mo ago	NCT05780567
Sichuan Baili Pharmaceutical Co., …	A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) Asset: BL-B01D1	Non-small Cell Lung Cancer	Active Not Recruiting	Q4 2026 2026-12 (est.)	Estimated · fresh Updated 3mo ago	NCT06382129
Sichuan Baili Pharmaceutical Co., …	A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) Asset: BL-B01D1	Small Cell Lung Cancer	Active Not Recruiting	Q4 2026 2026-12 (est.)	Estimated · fresh Updated 3mo ago	NCT06500026
NaviFUS Corporation	A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients Asset: Bevacizumab	Glioblastoma Multiforme +7	Recruiting	Q4 2026 2026-12-31 (est.)	Estimated · fresh Updated 3mo ago	NCT06496971
Clarity Pharmaceuticals Ltd	64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer Asset: 64Cu-SAR-bisPSMA	Prostate Cancer +5	Active Not Recruiting	Q4 2026 2026-12-31 (est.)	Estimated · fresh Updated 3mo ago	NCT06970847
RayzeBio, Inc.	Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy Asset: RYZ101	GEP-NET +6	Recruiting	Q4 2026 2026-12 (est.)	Estimated · fresh Updated 4mo ago	NCT05477576
Vergent Bioscience, Inc.	Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung Asset: Abenacianine	Lung Cancer +1	Recruiting	Q4 2026 2026-12 (est.)	Estimated · fresh Updated 4mo ago	NCT07499674
Greenwich LifeSciences, Inc.	Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects Asset: Placebo	Breast Cancer	Recruiting	Q4 2026 2026-12 (est.)	Estimated · fresh Updated 4mo ago	NCT05232916
Suzhou Suncadia Biopharmaceuticals…	A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC Asset: SHR-A2009 monotherapy	Non-small Cell Lung Cancer	Active Not Recruiting	Q4 2026 2026-12 (est.)	Estimated · fresh Updated 4mo ago	NCT06671379
Akeso	AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer Asset: AK112	Triple-Negative Breast Cancer (TNBC)	Recruiting	Q4 2026 2026-12 (est.)	Estimated · fresh Updated 4mo ago	NCT06767527
Aldeyra Therapeutics, Inc.	A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma Asset: ICM ADX-2191 injection	Primary Vitreoretinal Lymphoma	Recruiting	Q4 2026 2026-12 (est.)	Estimated · fresh Updated 5mo ago	NCT07402876
Gilead Sciences	Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) Asset: Sacituzumab Govitecan-hziy	Metastatic Breast Cancer	Active Not Recruiting	Q4 2026 2026-12 (est.)	Estimated · fresh Updated 5mo ago	NCT04639986
Sichuan Kelun-Biotech Biopharmaceu…	A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Asset: SKB264	Non-Small Cell Lung Cancer	Active Not Recruiting	Q4 2026 2026-12 (est.)	Estimated · fresh Updated 5mo ago	NCT06711900
Shandong Suncadia Medicine Co., Ltd.	A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer Asset: HRS-8080 Tablet	Locally Advanced Breast Cancer +1	Recruiting	Q4 2026 2026-12 (est.)	Estimated · fresh Updated 6mo ago	NCT07024173
Guangzhou Gloria Biosciences Co., …	Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients Asset: Motixafortide+G-CSF	Multiple Myeloma	Recruiting	Q4 2026 2026-12-31 (est.)	Estimated · aging Updated 7mo ago	NCT06514508
Kartos Therapeutics, Inc.	Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib Asset: Navtemadlin	Myelofibrosis +4	Recruiting	Q4 2026 2026-12-31 (est.)	Estimated · aging Updated 10mo ago	NCT06479135
Qilu Pharmaceutical Co., Ltd.	Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) Asset: QL2107	Carcinoma, Non-Small-Cell Lung	Not Yet Recruiting	Q4 2026 2026-12-31 (est.)	Estimated · aging Updated 10mo ago	NCT07162883
Jiangsu HengRui Medicine Co., Ltd.	A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane Asset: SHR-A1811	HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane	Active Not Recruiting	Q4 2026 2026-12-31 (est.)	Estimated · aging Updated 11mo ago	NCT05424835
TVAX Biomedical	Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) Asset: TVI-Brain-1	Glioblastoma Multiforme of Brain	Active Not Recruiting	Q4 2026 2026-12 (est.)	Estimated · stale Updated 13mo ago	NCT05685004
Qilu Pharmaceutical Co., Ltd.	A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC Asset: QL2107	NSCLC	Recruiting	Q4 2026 2026-12 (est.)	Estimated · stale Updated 13mo ago	NCT06754644
Changchun GeneScience Pharmaceutic…	Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase Asset: Nano-crystalline Megestrol Acetate Oral Suspension	Extensive-stage Small Cell Lung Cancer (ES-SCLC) +1	Not Yet Recruiting	Q4 2026 2026-12-31 (est.)	Estimated · stale Updated 14mo ago	NCT06961201
Chia Tai Tianqing Pharmaceutical G…	A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) Asset: AK105 Injection	Advanced Hepatocellular Carcinoma (HCC)	Active Not Recruiting	Q4 2026 2026-12 (est.)	Estimated · stale Updated 17mo ago	NCT04344158
Jiangsu HengRui Medicine Co., Ltd.	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Asset: Fuzuloparib , Abiraterone acetate and Prednisone	Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Active Not Recruiting	Q4 2026 2026-12-31 (est.)	Estimated · stale Updated 19mo ago	NCT04691804
Mabscale, LLC	A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer Asset: Bevacizumab	Non-Small Cell Lung Cancer	Recruiting	Q4 2026 2026-12 (est.)	Estimated · stale Updated 23mo ago	NCT05654454
RemeGen Co., Ltd.	DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy Asset: Disitamab Vedotin Injection	Gastric Cancer +1	Recruiting	Q4 2026 2026-12 (est.)	Estimated · stale Updated 27mo ago	NCT06221748
RemeGen Co., Ltd.	A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma Asset: RC48-ADC	Urothelial Carcinoma +1	Recruiting	Q4 2026 2026-12-31 (est.)	Estimated · stale Updated 31mo ago	NCT05302284
GC Cell Corporation	Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer Asset: Immuncell-LC	Pancreatic Ductal Adenocarcinoma	Recruiting	Q4 2026 2026-12 (est.)	Estimated · stale Updated 56mo ago	NCT04969731
Merck Sharp & Dohme LLC	A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) Asset: Sacituzumab tirumotecan	Gastroesophageal Cancer	Active Not Recruiting	Q1 2027 2027-01-04 (est.)	Estimated · fresh Updated 5mo ago	NCT06356311
Celgene	A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Asset: mezigdomide	Relapsed or Refractory Multiple Myeloma	Recruiting	Q1 2027 2027-01-10 (est.)	Estimated · fresh Updated 4mo ago	NCT05519085
FutureGen Biopharmaceutical (Beiji…	M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. Asset: M108 monoclonal antibody	Locally Advanced Unresectable or Metastatic Gastric Cancer +1	Recruiting	Q1 2027 2027-01-11 (est.)	Estimated · stale Updated 29mo ago	NCT06177041
Merck Sharp & Dohme LLC	Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) Asset: Sacituzumab Govitecan	Carcinoma, Non-Small-Cell Lung	Active Not Recruiting	Q1 2027 2027-01-12 (est.)	Estimated · aging Updated 7mo ago	NCT05609968
IDEAYA Biosciences	IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Asset: IDE196	Metastatic Uveal Melanoma	Active Not Recruiting	Q1 2027 2027-01-15 (est.)	Estimated · fresh Updated 5mo ago	NCT05987332
Biotheus Inc.	PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer Asset: PM8002	SCLC	Active Not Recruiting	Q1 2027 2027-01-25 (est.)	Estimated · stale Updated 19mo ago	NCT06616532
Novartis Pharmaceuticals	Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. Asset: Alpelisib	Breast Cancer	Active Not Recruiting	Q1 2027 2027-01-28 (est.)	Estimated · fresh Updated 3mo ago	NCT05038735
Shanghai Runshi Pharmaceutical Tec…	A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma Asset: simmitinib	Advanced Oesophageal Squamous Cell Carcinoma	Not Yet Recruiting	Q1 2027 2027-01-30 (est.)	Estimated · stale Updated 21mo ago	NCT06656091
Merck Sharp & Dohme LLC	Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) Asset: Pembrolizumab	Urinary Bladder Neoplasms	Active Not Recruiting	Q1 2027 2027-01-31 (est.)	Estimated · stale Updated 20mo ago	NCT04241185
Resilience	Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only	Cancer	Recruiting	Q1 2027 2027-01 (est.)	Estimated · fresh Updated 3mo ago	NCT06867705
Chia Tai Tianqing Pharmaceutical G…	A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma Asset: AL2846 Capsules	Thyroid Cancer	Recruiting	Q1 2027 2027-01 (est.)	Estimated · aging Updated 7mo ago	NCT06860971
NX Development Corp	Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302) Asset: Gleolan	Ovarian Cancer	Recruiting	Q1 2027 2027-01 (est.)	Estimated · aging Updated 10mo ago	NCT05804370
Biocad	A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma Asset: BCD-217	Melanoma Stage III +1	Active Not Recruiting	Q1 2027 2027-01 (est.)	Estimated · aging Updated 12mo ago	NCT05751928
Loxo Oncology, Inc.	Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) Asset: Pirtobrutinib	Lymphoma, Mantle-Cell	Active Not Recruiting	Q1 2027 2027-01 (est.)	Estimated · stale Updated 14mo ago	NCT04662255
Acerta Pharma BV	Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL Asset: Acalabrutinib	Chronic Lymphocytic Leukemia	Active Not Recruiting	Q1 2027 2027-01-31 (est.)	Estimated · stale Updated 19mo ago	NCT03836261
Akeso	A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Asset: AK117 in combination with AK112	Head and Neck Squamous Cell Carcinoma	Recruiting	Q1 2027 2027-01 (est.)	Estimated · stale Updated 20mo ago	NCT06601335
Chia Tai Tianqing Pharmaceutical G…	A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer Asset: TQB2102 for Injection	Breast Cancer	Not Yet Recruiting	Q1 2027 2027-01 (est.)	Estimated · stale Updated 23mo ago	NCT06561607
Merck Sharp & Dohme LLC	Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) Asset: pembrolizumab	Esophageal Squamous Cell Carcinoma (ESCC) +2	Active Not Recruiting	Q1 2027 2027-02-01 (est.)	Estimated · stale Updated 20mo ago	NCT04210115
GlaxoSmithKline	A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) Asset: Dostarlimab	Lung Cancer, Non-Small Cell	Active Not Recruiting	Q1 2027 2027-02-02 (est.)	Estimated · aging Updated 10mo ago	NCT06472076
Epizyme, Inc.	A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. Asset: Tazemetostat	Relapsed/Refractory Follicular Lymphoma +2	Active Not Recruiting	Q1 2027 2027-02-13 (est.)	Estimated · fresh Updated 3mo ago	NCT04224493
Acerta Pharma BV	A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL Asset: Acalabrutinib	Lymphoma, Mantle Cell	Active Not Recruiting	Q1 2027 2027-02-15 (est.)	Estimated · fresh Updated 5mo ago	NCT02972840
Hoffmann-La Roche	A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) Asset: Giredestrant	Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer	Recruiting	Q1 2027 2027-02-19 (est.)	Estimated · fresh Updated 3mo ago	NCT06065748
AstraZeneca	Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T) Asset: Osimertinib	Cancer	Active Not Recruiting	Q1 2027 2027-02-22 (est.)	Estimated · fresh Updated 3mo ago	NCT05629234
Acerta Pharma BV	A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) Asset: acalabrutinib	Diffuse Large B-Cell Lymphoma	Active Not Recruiting	Q1 2027 2027-02-22 (est.)	Estimated · fresh Updated 4mo ago	NCT04529772
Novartis Pharmaceuticals	Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation Asset: Alpelisib	Advanced HER2+Breast Cancer	Active Not Recruiting	Q1 2027 2027-02-26 (est.)	Estimated · fresh Updated 4mo ago	NCT04208178
Genmab	Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer Asset: Rina-S	Platinum-resistant Ovarian Cancer	Active Not Recruiting	Q1 2027 2027-02 (est.)	Estimated · fresh Updated 5mo ago	NCT06619236
Gilead Sciences	Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Asset: Sacituzumab Govitecan-hziy	Triple Negative Breast Cancer +1	Active Not Recruiting	Q1 2027 2027-02 (est.)	Estimated · aging Updated 10mo ago	NCT05382286
Celltrion	A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer Asset: CT-P51	Non Squamous Non Small Cell Lung Cancer	Active Not Recruiting	Q1 2027 2027-02 (est.)	Estimated · stale Updated 15mo ago	NCT06939595
Hansoh BioMedical R&D Company	HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer Asset: HS-20089	Ovarian Cancer	Recruiting	Q1 2027 2027-03-07 (est.)	Estimated · aging Updated 7mo ago	NCT06855069
Bristol-Myers Squibb	A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer Asset: Nivolumab	Renal Cell Carcinoma	Active Not Recruiting	Q1 2027 2027-03-11 (est.)	Estimated · fresh Updated 6mo ago	NCT03873402
Regeneron Pharmaceuticals	A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) Asset: fianlimab	Melanoma	Recruiting	Q1 2027 2027-03-22 (est.)	Estimated · fresh Updated 5mo ago	NCT06246916
Shanghai JMT-Bio Inc.	JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations Asset: JMT101 Injection	Local Advanced or Metastatic NSCLC	Not Yet Recruiting	Q1 2027 2027-03-26 (est.)	Estimated · stale Updated 27mo ago	NCT06380348
Jiangsu HengRui Medicine Co., Ltd.	A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer Asset: Rezvilutamide Tablets	Metastatic Hormone-sensitive Prostate Cancer (mHSPC)	Recruiting	Q1 2027 2027-03 (est.)	Estimated · fresh Updated 6mo ago	NCT07241416
Novartis Pharmaceuticals	Study of Out of Specification for Tisagenlecleucel Asset: CTL019	B-cell Acute Lymphoblastic Leukemia +1	Recruiting	Q1 2027 2027-03-31 (est.)	Estimated · fresh Updated 3mo ago	NCT04094311
TuHURA Biosciences, Inc.	Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma Asset: IFx-Hu2.0	Advanced Or Metastatic Merkel Cell Carcinoma	Recruiting	Q1 2027 2027-03-31 (est.)	Estimated · fresh Updated 3mo ago	NCT06947928
Hoffmann-La Roche	A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy Asset: Tiragolumab	Esophageal Squamous Cell Carcinoma	Active Not Recruiting	Q1 2027 2027-03-31 (est.)	Estimated · fresh Updated 3mo ago	NCT04543617
Quetzal Therapeutics	Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia Asset: QTX-2101 + ATRA	Acute Promyelocytic Leukemia (APL) +4	Recruiting	Q1 2027 2027-03 (est.)	Estimated · fresh Updated 3mo ago	NCT07504458
ABX advanced biochemical compounds…	Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer Asset: [18F]PSMA-1007	Prostate Cancer	Recruiting	Q1 2027 2027-03 (est.)	Estimated · fresh Updated 3mo ago	NCT06122584
Suzhou Suncadia Biopharmaceuticals…	A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma Asset: SHR-A1912 Injection	Diffuse Large B-cell Lymphoma	Recruiting	Q1 2027 2027-03 (est.)	Estimated · aging Updated 8mo ago	NCT06929624
BeOne Medicines	A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation Asset: zanubrutinib	Mantle Cell Lymphoma; Non-Hodgkin Lymphoma	Active Not Recruiting	Q1 2027 2027-03 (est.)	Estimated · aging Updated 10mo ago	NCT04002297
Hangzhou Sumgen Biotech Co., Ltd.	A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients Asset: SG301 Injection	Relapsed/Refractory Multiple Myeloma	Recruiting	Q1 2027 2027-03-31 (est.)	Estimated · stale Updated 13mo ago	NCT06508983
Seattle Project Corporation	A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer Asset: GRT-C901	Colorectal Neoplasms	Active Not Recruiting	Q1 2027 2027-03 (est.)	Estimated · stale Updated 14mo ago	NCT05141721
Pierre Fabre Medicament	Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. Asset: Encorafenib and Binimetinib	Melanoma	Active Not Recruiting	Q1 2027 2027-03-31 (est.)	Estimated · stale Updated 32mo ago	NCT05270044
Jiangsu Famous Medical Technology …	Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer Asset: XLJDOD compound granule	Colon Cancer	Recruiting	Q2 2027 2027-04-01 (est.)	Estimated · stale Updated 19mo ago	NCT05709249
AstraZeneca	Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib Asset: Olaparib	Ovarian Cancer +1	Active Not Recruiting	Q2 2027 2027-04-06 (est.)	Estimated · fresh Updated 3mo ago	NCT04421963
Celgene	Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) Asset: bb2121	Multiple Myeloma	Completed	Q2 2027 2027-04-08 (est.)	Estimated · stale Updated 43mo ago	NCT03651128
Shanghai Henlius Biotech	A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer Asset: HLX17	Non-Squamous Non-Small Cell Lung Cancer	Not Yet Recruiting	Q2 2027 2027-04-09 (est.)	Estimated · stale Updated 17mo ago	NCT06847334
AstraZeneca	A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy Asset: Camizestrant	Breast Cancer, Early Breast Cancer	Recruiting	Q2 2027 2027-04-20 (est.)	Estimated · fresh Updated 3mo ago	NCT05774951
LeonaBio	Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Asset: Lasofoxifene in combination with abemaciclib	Metastatic Breast Cancer	Recruiting	Q2 2027 2027-04 (est.)	Estimated · fresh Updated 3mo ago	NCT05696626
Taiho Oncology, Inc.	Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. Asset: futibatinib	Advanced/Metastatic Cancer	Enrolling By Invitation	Q2 2027 2027-04 (est.)	Estimated · fresh Updated 3mo ago	NCT06506955
Daiichi Sankyo	A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer Asset: Ifinatamab deruxtecan	Small Cell Lung Cancer	Recruiting	Q2 2027 2027-04-30 (est.)	Estimated · fresh Updated 5mo ago	NCT06203210
AbbVie	Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Asset: Mirvetuximab soravtansine plus Bevacizumab	Ovarian Cancer +2	Active Not Recruiting	Q2 2027 2027-04 (est.)	Estimated · fresh Updated 5mo ago	NCT05445778
mAbxience Research S.L.	Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma Asset: MB11 (Proposed Nivolumab Biosimilar)	Advanced (Unresectable or Metastatic) Melanoma	Recruiting	Q2 2027 2027-04 (est.)	Estimated · fresh Updated 6mo ago	NCT07221734
Shanghai Fosun Pharmaceutical Indu…	FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration Asset: Luvometinib	Low-grade Glioma +2	Not Yet Recruiting	Q2 2027 2027-04-30 (est.)	Estimated · stale Updated 13mo ago	NCT07004075
Merck Sharp & Dohme LLC	Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) Asset: Sacituzumab tirumotecan	Non-small Cell Lung Cancer (NSCLC)	Active Not Recruiting	Q2 2027 2027-05-10 (est.)	Estimated · fresh Updated 3mo ago	NCT06074588
Regeneron Pharmaceuticals	A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma Asset: Odronextamab	B-Cell Non-Hodgkin Lymphoma (B-NHL)	Active Not Recruiting	Q2 2027 2027-05-14 (est.)	Estimated · fresh Updated 3mo ago	NCT06230224
Akeso	A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer Asset: Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine	Pancreatic Cancer	Recruiting	Q2 2027 2027-05-14 (est.)	Estimated · fresh Updated 4mo ago	NCT06953999
Merck Sharp & Dohme LLC	A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) Asset: Nemtabrutinib	Chronic Lymphocytic Leukemia +1	Active Not Recruiting	Q2 2027 2027-05-19 (est.)	Estimated · fresh Updated 4mo ago	NCT05624554
Merck Sharp & Dohme LLC	Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) Asset: pembrolizumab	Endometrial Neoplasms	Active Not Recruiting	Q2 2027 2027-05-27 (est.)	Estimated · stale Updated 20mo ago	NCT05173987
Sichuan Kelun-Biotech Biopharmaceu…	A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Asset: SKB264	Non-Small Cell Lung Cancer	Active Not Recruiting	Q2 2027 2027-05 (est.)	Estimated · aging Updated 7mo ago	NCT06670196
Priothera SAS	Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT Asset: mocravimod	Adult Acute Myeloid Leukemia	Recruiting	Q2 2027 2027-05 (est.)	Estimated · fresh Updated 3mo ago	NCT05429632
Jiangsu HengRui Medicine Co., Ltd.	A Study of SHR-A1811 in Subjects With Ovarian Cancer Asset: SHR-A1811	Ovarian Cancer	Recruiting	Q2 2027 2027-05 (est.)	Estimated · fresh Updated 3mo ago	NCT06828354
Akeso	Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer Asset: Ivonescimab, docetaxel	Non-Small Cell Lung Cancer	Recruiting	Q2 2027 2027-05 (est.)	Estimated · fresh Updated 3mo ago	NCT06928389
Sichuan Baili Pharmaceutical Co., …	A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer Asset: BL-M07D1	HER2-low Breast Cancer	Recruiting	Q2 2027 2027-05 (est.)	Estimated · fresh Updated 6mo ago	NCT06957886
Suzhou Immunofoco Biotechnology Co…	A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients Asset: CAR T cells	Gastric Adenocarcinoma	Recruiting	Q2 2027 2027-05-31 (est.)	Estimated · aging Updated 9mo ago	NCT07103668
Qilu Pharmaceutical Co., Ltd.	A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer Asset: MHB088C for Injection	Small Cell Lung Cancer Extensive Stage	Recruiting	Q2 2027 2027-05 (est.)	Estimated · stale Updated 13mo ago	NCT06954246
InSightec	Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets Asset: Pembrolizumab	Brain Tumor +1	Recruiting	Q2 2027 2027-06-01 (est.)	Estimated · fresh Updated 3mo ago	NCT05317858
Shanghai Henlius Biotech	A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer Asset: HLX22	Gastroesophageal-junction Cancer +3	Recruiting	Q2 2027 2027-06-01 (est.)	Estimated · fresh Updated 5mo ago	NCT06532006
Shanghai JMT-Bio Inc.	The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer Asset: JMT101	Metastatic Colorectal Cancer (mCRC)	Not Yet Recruiting	Q2 2027 2027-06-01 (est.)	Estimated · aging Updated 11mo ago	NCT07134205
Novartis Pharmaceuticals	An Extension Study for Patients Previously Enrolled in Studies With Pelabresib Asset: Pelabresib	Hematologic Malignancy +2	Recruiting	Q2 2027 2027-06-02 (est.)	Estimated · stale Updated 13mo ago	NCT06401356
Shanghai Henlius Biotech	A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma Asset: HLX13	Hepatocellular Carcinoma (HCC)	Not Yet Recruiting	Q2 2027 2027-06-06 (est.)	Estimated · stale Updated 17mo ago	NCT06841185
Merck Sharp & Dohme LLC	A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study Asset: Pembrolizumab	Carcinoma, Renal Cell	Active Not Recruiting	Q2 2027 2027-06-07 (est.)	Estimated · aging Updated 8mo ago	NCT05899049
Bristol-Myers Squibb	ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions Asset: Luspatercept	Myelodysplastic Syndromes	Active Not Recruiting	Q2 2027 2027-06-25 (est.)	Estimated · fresh Updated 4mo ago	NCT05949684
Amgen	A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) Asset: Sotorasib	Non-Small Cell Lung Cancer (NSCLC)	Recruiting	Q2 2027 2027-06-30 (est.)	Estimated · fresh Updated 3mo ago	NCT05920356
Gilead Sciences	Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) Asset: Sacituzumab govitecan-hziy (SG)	Triple Negative Breast Cancer	Recruiting	Q2 2027 2027-06 (est.)	Estimated · fresh Updated 6mo ago	NCT05633654
BeiGene	Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma Asset: Tislelizumab	Urothelial Carcinoma	Active Not Recruiting	Q2 2027 2027-06-30 (est.)	Estimated · fresh Updated 3mo ago	NCT03967977
Sichuan Baili Pharmaceutical Co., …	A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01) Asset: BL-B01D1	Urothelial Carcinoma	Recruiting	Q2 2027 2027-06 (est.)	Estimated · fresh Updated 3mo ago	NCT06857175
Sichuan Baili Pharmaceutical Co., …	A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) Asset: BL-B01D1	Epithelial Ovarian Cancer +2	Recruiting	Q2 2027 2027-06 (est.)	Estimated · fresh Updated 3mo ago	NCT06994195
Hoffmann-La Roche	An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) Asset: Atezolizumab	Neoplasms	Active Not Recruiting	Q2 2027 2027-06-30 (est.)	Estimated · fresh Updated 3mo ago	NCT05112965
Immutep S.A.S.	Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) Asset: eftilagimod alfa	Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	Active Not Recruiting	Q2 2027 2027-06 (est.)	Estimated · fresh Updated 4mo ago	NCT06726265
Pharmacosmos A/S	Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer Asset: Trilaciclib	Limited Stage Small Cell Lung Cancer	Recruiting	Q2 2027 2027-06 (est.)	Estimated · fresh Updated 4mo ago	NCT07473128
Day One Biopharmaceuticals, Inc.	DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) Asset: Tovorafenib	Low-grade Glioma +2	Active Not Recruiting	Q2 2027 2027-06 (est.)	Estimated · fresh Updated 5mo ago	NCT05566795
AstraZeneca	A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features Asset: Datopotamab Deruxtecan	Non-small Cell Lung Cancer	Active Not Recruiting	Q2 2027 2027-06-30 (est.)	Estimated · fresh Updated 6mo ago	NCT06564844
Changchun GeneScience Pharmaceutic…	Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma Asset: Nanocrystalline Megestrol Acetate	Cachexia +1	Not Yet Recruiting	Q2 2027 2027-06-30 (est.)	Estimated · fresh Updated 6mo ago	NCT07356037
SDK Therapeutics, Inc.	A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301) Asset: Oral ATO	Acute Promyelocytic Leukemia (APL) +8	Not Yet Recruiting	Q2 2027 2027-06 (est.)	Estimated · aging Updated 7mo ago	NCT07296445
Genfleet Therapeutics (Shanghai) I…	Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer Asset: GFH375	Metastatic Pancreatic Cancer	Recruiting	Q2 2027 2027-06 (est.)	Estimated · aging Updated 7mo ago	NCT07262567
Sichuan Baili Pharmaceutical Co., …	A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma Asset: BL-M07D1	Gastric Adenocarcinoma +1	Recruiting	Q2 2027 2027-06 (est.)	Estimated · aging Updated 8mo ago	NCT07152405
Qilu Pharmaceutical Co., Ltd.	A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer Asset: ESG401	Triple-Negative Breast Cancer (TNBC)	Recruiting	Q2 2027 2027-06 (est.)	Estimated · aging Updated 10mo ago	NCT06732323
ITM Solucin GmbH	Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE Asset: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT	Neuroendocrine Tumors	Active Not Recruiting	Q2 2027 2027-06 (est.)	Estimated · aging Updated 10mo ago	NCT04919226
Changchun GeneScience Pharmaceutic…	Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer Asset: Nano-crystalline Megestrol Acetate Oral Suspension	Non-small Cell Lung Cancer	Recruiting	Q2 2027 2027-06-30 (est.)	Estimated · aging Updated 10mo ago	NCT07150663
Lepu Biopharma Co., Ltd.	A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer Asset: MRG004A plus best supportive care	Advanced Pancreatic Cancer	Not Yet Recruiting	Q2 2027 2027-06 (est.)	Estimated · aging Updated 11mo ago	NCT07138846
Innovent Biologics (Suzhou) Co. Ltd.	A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002) Asset: IBI343	Pancreatic Cancer	Recruiting	Q2 2027 2027-06-30 (est.)	Estimated · aging Updated 11mo ago	NCT07066098
Qilu Pharmaceutical Co., Ltd.	A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer Asset: ESG401	Metastatic Breast Cancer	Recruiting	Q2 2027 2027-06-30 (est.)	Estimated · stale Updated 13mo ago	NCT06383767
Changchun GeneScience Pharmaceutic…	Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis Asset: Nano-crystalline Megestrol Acetate Oral Suspension	Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity +1	Not Yet Recruiting	Q2 2027 2027-06-30 (est.)	Estimated · stale Updated 14mo ago	NCT06961188
Genmab	A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Asset: Epcoritamab	Diffuse Large B-Cell Lymphoma	Active Not Recruiting	Q2 2027 2027-06 (est.)	Estimated · stale Updated 18mo ago	NCT05578976
InnoBM Pharmaceuticals Co., Ltd.	A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma	Hepatocellular Carcinoma Non-Resectable	Not Yet Recruiting	Q2 2027 2027-06 (est.)	Estimated · stale Updated 18mo ago	NCT06779461
Changchun GeneScience Pharmaceutic…	Nano-crystalline Megestrol Acetate for Adjuvant Treatment in High-risk Head and Neck Squamous Cell Carcinoma After Surgery. Asset: Nano-crystalline Megestrol Acetate Oral Suspension	Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors	Not Yet Recruiting	Q2 2027 2027-06-30 (est.)	Estimated · stale Updated 18mo ago	NCT06772428
Jiangsu HengRui Medicine Co., Ltd.	SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen Asset: SHR-A1811	HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma	Recruiting	Q2 2027 2027-06-30 (est.)	Estimated · stale Updated 30mo ago	NCT06123494
Shanghai Yizhong Pharmaceutical Co…	Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer Asset: paclitaxel polymeric micelles for injection	Pancreatic Cancer Metastatic	Recruiting	Q3 2027 2027-07-01 (est.)	Estimated · fresh Updated 5mo ago	NCT06752811
Shijiazhuang Yiling Pharmaceutical…	A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE) Asset: XY0206	Acute Myeloid Leukemia With FLT3/ITD Mutation	Not Yet Recruiting	Q3 2027 2027-07-01 (est.)	Estimated · stale Updated 38mo ago	NCT05876832
Amgen	Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab Asset: Tarlatamab	Extensive-Stage Small-Cell Lung Cancer +1	Active Not Recruiting	Q3 2027 2027-07-05 (est.)	Estimated · aging Updated 7mo ago	NCT06211036
Merck Sharp & Dohme LLC	A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) Asset: Sacituzumab tirumotecan	Breast Neoplasms	Recruiting	Q3 2027 2027-07-11 (est.)	Estimated · fresh Updated 4mo ago	NCT06312176
AstraZeneca	A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Asset: Acalabrutinib	Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Active Not Recruiting	Q3 2027 2027-07-15 (est.)	Estimated · fresh Updated 5mo ago	NCT05057494

Unlock 218 more oncology readouts · plus filters on the full calendar

Upgrade to Pro

About this calendar

Dates anchor on the ClinicalTrials.gov primary completion date — the only public, structured signal — and are graded by date type (actual vs sponsor-estimated) and how recently the record was updated. Sponsor-estimated dates can slip silently, so treat each as a current target rather than a guarantee. See the full readout calendar for all areas and filters.